In the previously presented DESTINY Gastric-01 study,9 trastuzumab deruxtecan had demonstrated efficacy in Asian HER2-positive gastric cancer patients but had not yet been evaluated in non-Asian patients. This evidence concerns the gene ERBB2 and gastric cancer.